Palisade Bio (PALI) Assets Average (2011 - 2026)
Palisade Bio (PALI) reported Assets Average of $133.8 million for Q1 2026, up 1303.56% year-over-year from $9.5 million in Q1 2025, and up 89.4% on a QoQ basis from $70.7 million in Q4 2025.
Palisade Bio (PALI) has 16 years of Assets Average data on file, last reported at $133.8 million in Q1 2026.
- Quarterly Assets Average rose 1303.56% year-over-year to $133.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.8 million (up 1303.56% YoY) and the FY2025 annual result came in at $72.6 million, up 482.48% from the prior year.
- Assets Average rose to $133.8 million in Q1 2026 per PALI's latest filing, from $70.7 million in the prior quarter.
- Across five years, Assets Average topped out at $133.8 million in Q1 2026 and bottomed at $6.8 million in Q3 2025.
- The 5-year median for Assets Average is $12.8 million (2024), against an average of $22.8 million.
- The widest annual swing landed in 2025, when Assets Average slumped 41.79%; it then jumped 1303.56% in 2026.
- Tracing PALI's Assets Average over 5 years: stood at $16.0 million in 2022, then slipped by 2.84% to $15.6 million in 2023, then slumped by 35.04% to $10.1 million in 2024, then surged by 599.04% to $70.7 million in 2025, then jumped by 89.4% to $133.8 million in 2026.
- Per Business Quant, the three latest PALI Assets Average figures stand at $133.8 million (Q1 2026), $70.7 million (Q4 2025), and $6.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 133.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 133.83 Mn |
| Dec 31, 2025 | 70.66 Mn |
| Sep 30, 2025 | 6.82 Mn |
| Jun 30, 2025 | 7.43 Mn |
| Mar 31, 2025 | 9.54 Mn |
| Dec 31, 2024 | 10.11 Mn |
| Sep 30, 2024 | 11.10 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Mar 31, 2024 | 13.35 Mn |
| Dec 31, 2023 | 15.56 Mn |
| Sep 30, 2023 | 17.68 Mn |
| Jun 30, 2023 | 16.78 Mn |
| Mar 31, 2023 | 15.51 Mn |
| Dec 31, 2022 | 16.01 Mn |
| Sep 30, 2022 | 12.04 Mn |
| Jun 30, 2022 | 8.08 Mn |
| Mar 31, 2022 | 10.43 Mn |
| Dec 31, 2021 | 14.39 Mn |
| Sep 30, 2021 | 15.61 Mn |
| Jun 30, 2021 | 11.93 Mn |
| Mar 31, 2021 | 5.97 Mn |
| Dec 31, 2020 | 9.09 Mn |
| Sep 30, 2020 | 16.14 Mn |
| Jun 30, 2020 | 14.23 Mn |
| Mar 31, 2020 | 8.97 Mn |
| Dec 31, 2019 | 7.76 Mn |
| Sep 30, 2019 | 6.23 Mn |
| Jun 30, 2019 | 4.46 Mn |
| Mar 31, 2019 | 6.55 Mn |
| Dec 31, 2018 | 7.70 Mn |
| Sep 30, 2018 | 8.48 Mn |
| Jun 30, 2018 | 10.39 Mn |
| Mar 31, 2018 | 12.72 Mn |
| Dec 31, 2017 | 15.04 Mn |
| Sep 30, 2017 | 14.73 Mn |
| Jun 30, 2017 | 16.00 Mn |
| Mar 31, 2017 | 20.67 Mn |
| Dec 31, 2016 | 15.53 Mn |
| Sep 30, 2016 | 10.87 Mn |
| Jun 30, 2016 | 11.75 Mn |
| Mar 31, 2016 | 12.57 Mn |
| Dec 31, 2015 | 18.05 Mn |
| Sep 30, 2015 | 23.76 Mn |
| Jun 30, 2015 | 28.59 Mn |
| Mar 31, 2015 | 30.32 Mn |
| Dec 31, 2014 | 29.64 Mn |
| Sep 30, 2014 | 31.04 Mn |
| Jun 30, 2014 | 34.28 Mn |
| Mar 31, 2014 | 27.67 Mn |
| Dec 31, 2013 | 19.29 Mn |
| Sep 30, 2013 | 16.48 Mn |
| Jun 30, 2013 | 14.60 Mn |
| Mar 31, 2013 | 12.08 Mn |
| Dec 31, 2012 | 10.00 Mn |
| Sep 30, 2012 | 7.60 Mn |
| Jun 30, 2012 | 5.40 Mn |
| Mar 31, 2012 | 5.47 Mn |
| Dec 31, 2011 | 4.99 Mn |
| Sep 30, 2011 | 6.65 Mn |